Commit Biologics appoints Mikkel Wandahl Pedersen as Chief Scientific Officer

/in
  • Highly experienced leader with demonstrated track record of antibody-based drug discovery and pipeline advancement
  • Strengthens Commit’s leadership team after emerging from stealth with €16m seed financing
  • Dr Pedersen will spearhead research and development of Commit’s BiCETM technology as the Company moves towards drug candidate (DC) nomination

Aarhus, Denmark, 15 October 2024 – Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today announces the appointment of Mikkel Wandahl Pedersen as Chief Scientific Officer (CSO).

Read more..